Fig. 1 | npj Breast Cancer

Fig. 1

From: PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

Fig. 1

MAP3K1 alterations are associated with improved clinical benefit to PI3Ki and endocrine therapy in PIK3CAMUT ER+ breast cancers. a All detected alterations as assayed by IMPACT NGS assay across study patients. b Months on study swimmer plot organized by PIK3CA and MAP3K1 mutational status. Patient bars are colored according to reason for discontinuation. c Kaplan–Meier progression-free survival curves for patients based on presence/absence of MAP3K1 (top) or PIK3CA (bottom) alterations. Patients who discontinued study medication due to toxicity prior to detection of progression are censored events. P-value represents log-rank test. d Kaplan–Meier progression-free survival curves for patients based on PIK3CA/MAP3K1 status. Patients harboring alterations in both genes performed significantly better (p = 0.02; log-rank trend test), while patients with an alteration in only one of the pathways performed similarly to those with neither

Back to article page